LYVE1 and neoplasm: This result confirms increased tumor lymphatic vascularization of Ibtk+/- Eμ-myc compared to Ibtk+/+ Eμ-myc mice as shown by immunofluorescence with the specific lymphangiogenic marker Lyve1 [26] (Figure 2C).